Bristol Myers: conclusive results for Opdivo + Yervoy

(CercleFinance.com) - Bristol Myers Squibb today announced that a phase 3 trial evaluating Opdivo (nivolumab) + Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) met its primary endpoint of improving overall survival (OS).


Opdivo + Yervoy demonstrated a statistically and clinically significant improvement in OS compared to sorafenib or lenvatinib.

The overall survival benefit demonstrated by the Opdivo + Yervoy combination in the trial demonstrates its potential to improve outcomes over well-established treatment options, Bristol Myers Squibb said.

The company will conduct a full evaluation of the data and work with the investigators to share the results with the scientific community at an upcoming medical conference, as well as discuss them with health authorities.


Copyright (c) 2024 CercleFinance.com. All rights reserved.